Martinez Bueno A, Molina MA, Fielding A, et al. Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in ovarian cancer. ESMO 2017, abstract LBA42.
"Verlaag leeftijdsgrens bevolkingsonderzoek darmkanker naar 50 jaar"
dec 2019 | Endoscopie, Maag-darm-leveroncologie